Navigation Links
BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
Date:1/14/2009

ch statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking information. These risks include, but are not limited to, those associated with our capacity to finance our activities, the adequacy, timing, and results of our clinical trials, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, the success of research and development programs, reliance on subcontractors and key personnel, and other risks and uncertainties detailed from time-to-time in our filings with the Canadian securities commissions.

Readers should not place undue reliance on the forward-looking information, given that (i) our actual results could differ materially from a conclusion, forecast or projection in the forward-looking information, and (ii) certain material factors or assumptions which were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, could prove to be inaccurate. Additional information about (i) the material factors that could cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information, and (ii) the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, is contained in the Company's annual report and other documents filed from time to time with the Canadian securities commissions which are available at www.sedar.com. These statements speak only as of the date they are made, and we assume no obligation to revise such statements as a result of any event, circumst
'/>"/>

SOURCE BioSyntech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. West Concludes Agreement with Nektar
4. Workforce Alliance Concludes Three-Year Biotech Training Program
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... Boston, MA (PRWEB) August 21, 2014 ... collaboration company, has been recognized as one of ... 500 | 5000 magazine for the 2nd consecutive ... on its 33rd annual Inc. 500|5000, an exclusive ... list represents the most comprehensive look at the ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... Repligen,Corporation (Nasdaq: RGEN ) announced today that ... BMY ) in its lawsuit alleging,infringement of U.S. ... sale of Orencia(R) for the treatment of rheumatoid,arthritis. The ... of $5,000,000 and to pay royalties on the U.S. ...
... April 8 The Board of Molecular Vision ... acquisition,of Molecular Vision have now ceased. Acrongenomics has ... agreed. Given this, the Board of,Molecular Vision believes ... served,by bringing these discussions to a conclusion. Acrongenomics ...
... based strategic market research firm expands its presence in Europe ... and deepens its methodological expertise., ... the appointment of Penny Mesure as a Director based in ... support and,facilitate the continuing expansion of the company,s European and ...
Cached Biology Technology:Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit 2Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit 3Observant LLC Appoints Two New Directors to the Senior Management Team 2
(Date:8/21/2014)... National University (ANU) team has successfully replicated one of ... biological systems powered by sunlight which could manufacture hydrogen ... is sunlight. It is an exciting prospect to use ... safely," said Dr Kastoori Hingorani, from the ARC Centre ... School of Biology. , Hydrogen offers potential as a ...
(Date:8/20/2014)... HOUSTON, Aug. 20, 2014 George E. Fox, a John ... University of Houston (UH), was named a fellow in the ... (ISSOL). , Fox is one of four members ... Spain chosen as fellows in 2014. Fellows are elected ... With more than 500 members from more than 20 countries, ...
(Date:8/20/2014)... of Tennessee, Knoxville, research finds life can persist in ... was part of a team that examined waters and ... ice sheet and found the extreme environment supports microbial ... Jill Mikucki and her colleagues has implications for life ... the solar system. The findings are published in the ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... at the University of Leicester have released satellite images of ... which are currently sweeping across central and western Russia. ... University,s Earth Observation Science group have analysed and released still ... satellite image is available as both a true colour image ...
... soap can help build electrodes for cheaper lithium ion ... of Nano Letters . The one-step method will ... lithium ion-metal oxide batteries currently on the market. ... electrode materials," said material scientist Daiwon Choi of the ...
... Montreal, August 12, 2010 Dr. Jean-Philippe ... unit at the Institut de recherches cliniques de ... for modulating vascular permeability: the nitrosylation of beta-catenin ... have a possible impact on the treatment of ...
Cached Biology News:Fires around Moscow: A satellite perspective 2Wax, soap clean up obstacles to better batteries 2Wax, soap clean up obstacles to better batteries 3Wax, soap clean up obstacles to better batteries 4An IRCM researcher pinpoints the cellular mechanism responsible for modulating the permeability of blood vessels 2
Ready-to-use solution....
Applications: ISH...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: